CAR-T is increasingly clinically validated, but manufacturing remains a scaling limiter, with donor variability, patient-specific production and complex GMP workflows restricting throughput. A new industry overview highlights the shift from reactive process control toward predictive, earlier identification of cellular state changes that can signal failure risks. The report emphasizes the need for real-time analytics that can reveal what a cell is becoming, not only what it has already done, and frames dielectric-signature approaches as one route to earlier predictive control. The manufacturing focus aligns with investor and sponsor needs to reduce cost of goods, improve consistency and expand access—especially as CAR-T programs expand into earlier lines and larger patient pools.